Jacalyn Rosenblatt, MD
Hematology · Boston, MANPI 1750329058
Payments from drug & device makers
Across 223 payments — averaging $21,743 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.6M
- E.r. Squibb & Sons, L.L.C.$1.2M
- Bristol Myers Squibb$953K
- Pfizer$482K
- Acerta Pharma LLC$344K
- Janssen Research & Development, LLC$93K
- plus $139K from 7 others
Across 132 payments — averaging $4291.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$382K
- Pharmacyclics LLC, An Abbvie Company$92K
- Acerta Pharma LLC$28K
- Regeneron$25K
- Beigene (suzhou) Co., Ltd.$14K
- Beigene, Ltd.$10K
- plus $16K from 7 others
What the payments were for
- Consulting fees$453,05799%
- Travel & lodging$1,8150%
- Food & beverage$5540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $1,595,372 |
| E.r. Squibb & Sons, L.L.C. | 19 | $1,242,724 |
| Bristol Myers Squibb | 28 | $953,005 |
| Pfizer | 41 | $481,700 |
| Acerta Pharma LLC | 50 | $344,070 |
| Janssen Research & Development, LLC | 24 | $92,987 |
| Astrazeneca UK Limited | 30 | $73,945 |
| Sanofi US Services Inc. | 2 | $33,500 |
| Merck | 10 | $14,704 |
| Novartis | 3 | $11,651 |
| Johnson & Johnson | 2 | $1,710 |
| Gilead | 1 | $1,700 |
| Beigene, Ltd. | 1 | $1,600 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,848,669 in reported general payments places this provider in the 95th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 14 | $60 |
Paid to pharmacies, not to this prescriber.
Other hematology in Boston
- Omar NadeemBoston$22.8M
- Monique Hartley-BrownBoston$5.2M
- Shayna SarosiekBoston$4M
- David KuterBoston$3.1M
- Vaishali SanchorawalaBoston$2.9M
- Jerome RitzBoston$2M
- Andrew EvensBoston$1.1M
- Julie Erika HayduBoston$940K
- John SloanBoston$882K
- Salvia JainBoston$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.